This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

[video] Rite Aid's Full-Year Outlook Isn't What the Doctor Ordered

The video this transcript is based on appeared on December 19.

NEW YORK ( TheStreet) -- Drugstore chain Rite Aid reported solid third-quarter results on Thursday after a strong start to its flu-immunization program and the completed addition of Wellness stores.  However, shares of Rite Aid are falling after the company lowered its profit forecast and revenue outlook for the year.


Shares of Rite Aid (RAD) are falling on Thursday after reporting solid third-quarter earnings but lowering its profit forecast and revenue outlook for the year.

Rite Aid reported revenue of $6.36 billion, beating analysts' expectations of $6.32 billion.  The drugstore chain reported earnings per share of 4 cents, in line with estimates.

Rite Aid same same-store sales for the period grew 2.3% and it delivered growth in same-store prescription counts as well.  Chairman and Chief Executive John Standley attributed the results to a strong start to the company's flu-immunization program and its completion of additional Wellness stores.

However, for 2014, Rite Aid now expects net income to come in between 17 and 23 cents a share, below analysts' expectations of 24 cents a share and lower than its prior forecast of 18 cents to 27 cents a share.

At last check, shares were falling about 4.5% to $5.50.  In New York, I'm Brittany Umar for TheStreet.

Written by Brittany Umar in New York.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $108.47 -2.10%
FB $90.58 -2.00%
GOOG $627.32 -2.30%
TSLA $223.16 -3.80%
YHOO $31.97 0.31%


Chart of I:DJI
DOW 16,898.49 -13.80 -0.08%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,758.6880 -32.4640 -0.68%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs